These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2614487)

  • 1. Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis.
    Testa D; Caraceni T; Fetoni V
    J Neurol; 1989 Dec; 236(8):445-7. PubMed ID: 2614487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? The Italian ALS Study Group.
    Neurology; 1993 Dec; 43(12):2466-70. PubMed ID: 8255440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acids for amyotrophic lateral sclerosis / motor neuron disease.
    Parton M; Mitsumoto H; Leigh PN
    Cochrane Database Syst Rev; 2003; (4):CD003457. PubMed ID: 14583978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WITHDRAWN: Amino acids for amyotrophic lateral sclerosis / motor neuron disease.
    Parton M; Mitsumoto H; Leigh PN
    Cochrane Database Syst Rev; 2008 Apr; (2):CD003457. PubMed ID: 18425887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Branched-chain aminoacids in amyotrophic lateral sclerosis.
    Lancet; 1988 Sep; 2(8612):680-2. PubMed ID: 2901533
    [No Abstract]   [Full Text] [Related]  

  • 6. Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis.
    Plaitakis A; Smith J; Mandeli J; Yahr MD
    Lancet; 1988 May; 1(8593):1015-8. PubMed ID: 2896868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal glutamatergic mechanisms and branched-chain aminoacids in amyotrophic lateral sclerosis.
    Plaitakis A
    Lancet; 1989 Jan; 1(8630):157. PubMed ID: 2563069
    [No Abstract]   [Full Text] [Related]  

  • 8. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters.
    Ryberg H; Askmark H; Persson LI
    Acta Neurol Scand; 2003 Jul; 108(1):1-8. PubMed ID: 12807386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data.
    Tandan R; Bromberg MB; Forshew D; Fries TJ; Badger GJ; Carpenter J; Krusinski PB; Betts EF; Arciero K; Nau K
    Neurology; 1996 Nov; 47(5):1220-6. PubMed ID: 8909433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Branched-chain amino acids and ALS.
    Plaitakis A
    Neurology; 1994 Oct; 44(10):1982-3. PubMed ID: 7936265
    [No Abstract]   [Full Text] [Related]  

  • 11. The imbalance of brain large-chain aminoacid availability in amyotrophic lateral sclerosis patients treated with high doses of branched-chain aminoacids.
    Bastone A; Micheli A; Beghi E; Salmona M
    Neurochem Int; 1995 Dec; 27(6):467-72. PubMed ID: 8574175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiologic endpoint measures in a multicenter ALS drug trial.
    Bromberg MB; Fries TJ; Forshew DA; Tandan R
    J Neurol Sci; 2001 Feb; 184(1):51-5. PubMed ID: 11231032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of branched-chain amino acids on glutamate metabolism in amyotrophic lateral sclerosis.
    Gredal O; Møller SE
    J Neurol Sci; 1995 Mar; 129(1):40-3. PubMed ID: 7751843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis.
    Welty DF; Schielke GP; Rothstein JD
    Ann Pharmacother; 1995 Nov; 29(11):1164-7. PubMed ID: 8573965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased levels of p70S6 phosphorylation in the G93A mouse model of Amyotrophic Lateral Sclerosis and in valine-exposed cortical neurons in culture.
    Carunchio I; Curcio L; Pieri M; Pica F; Caioli S; Viscomi MT; Molinari M; Canu N; Bernardi G; Zona C
    Exp Neurol; 2010 Nov; 226(1):218-30. PubMed ID: 20832409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current therapies in motor neurone disease.
    Goonetilleke A
    Br J Hosp Med; 1995 Apr 5-18; 53(7):314-7. PubMed ID: 7788066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anomaly in the neurotransmitter amino acids in amyotrophic lateral sclerosis: a therapeutic application].
    Blin O; Desnuelle C; Guelton C; Aubrespy G; Ardissonne JP; Crevat A; Pouget J; Serratrice G
    Rev Neurol (Paris); 1991; 147(5):392-4. PubMed ID: 1677212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study.
    Malaguarnera M; Risino C; Cammalleri L; Malaguarnera L; Astuto M; Vecchio I; Rampello L
    Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):762-70. PubMed ID: 19357525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of bolus supplementation of branched-chain amino acids on skeletal muscle mass, strength, and function in patients with rheumatic disorders during glucocorticoid treatment.
    Yoshikawa N; Shimizu N; Uehara M; Oda A; Matsumiya R; Matsubara E; Kobayashi H; Hosono O; Kuribara-Souta A; Baba H; Nagamura F; Kiryu S; Tanaka H
    Mod Rheumatol; 2017 May; 27(3):508-517. PubMed ID: 27678151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.